See more : JD Health International Inc. (JDHIY) Income Statement Analysis – Financial Results
Complete financial analysis of Adial Pharmaceuticals, Inc. (ADIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adial Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Quintain Steel Co., LTD. (2017.TW) Income Statement Analysis – Financial Results
- Capita plc (CTAGF) Income Statement Analysis – Financial Results
- Paramount Resources Ltd. (PRMRF) Income Statement Analysis – Financial Results
- Morita Holdings Corporation (6455.T) Income Statement Analysis – Financial Results
- Alok Industries Limited (ALOKTEXT.BO) Income Statement Analysis – Financial Results
Adial Pharmaceuticals, Inc. (ADIL)
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 564.00 | 60.50K | 55.11K | 564.00 | 565.00 | 563.00 | 565.00 | 565.00 | 565.00 |
| Gross Profit | -564.00 | -60.50K | -55.11K | -564.00 | -565.00 | -563.00 | -565.00 | -565.00 | -565.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.27M | 4.18M | 8.40M | 5.85M | 3.97M | 368.46K | 182.11K | 146.14K | 322.11K |
| General & Administrative | 5.62M | 9.14M | 9.34M | 5.07M | 4.28M | 6.62M | 813.18K | 264.66K | 497.15K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.62M | 9.14M | 9.34M | 5.07M | 4.28M | 6.62M | 813.18K | 264.66K | 497.15K |
| Other Expenses | 0.00 | 0.00 | 46.49K | 2.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.89M | 13.32M | 17.74M | 10.93M | 8.24M | 6.99M | 995.29K | 410.81K | 819.26K |
| Cost & Expenses | 6.89M | 13.32M | 17.74M | 10.93M | 8.24M | 6.99M | 995.29K | 410.81K | 819.26K |
| Interest Income | 69.78K | 63.34K | 6.54K | 32.50K | 95.23K | 7.39K | 367.00 | 240.00 | 1.26K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.17M | 144.54K | 9.64K | 0.00 | |
| Depreciation & Amortization | 564.00 | 564.00 | 55.11K | 564.00 | 565.00 | 563.00 | 565.00 | 565.00 | 565.00 |
| EBITDA | -7.00M | -13.32M | -19.46M | -10.93M | -8.15M | -6.98M | -994.35K | -410.00K | -817.43K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.89M | -13.32M | -19.29M | -10.93M | -8.24M | -6.99M | -995.29K | -410.81K | -819.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -113.94K | 585.21K | -1.82M | 35.00K | -346.53K | -4.64M | -144.17K | -9.39K | 1.26K |
| Income Before Tax | -7.00M | -12.73M | -19.52M | -10.89M | -8.59M | -11.63M | -1.14M | -420.20K | -817.99K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -502.00 | -94.08K | -32.50K | -76.06K | -3.48M | 367.00 | 9.64K | 1.26K |
| Net Income | -7.00M | -12.73M | -19.42M | -10.86M | -8.59M | -11.63M | -1.14M | -420.20K | -817.99K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.44 | -11.98 | -26.12 | -21.79 | -21.80 | -61.10 | -5.20 | -2.20 | -4.28 |
| EPS Diluted | -5.44 | -11.98 | -26.12 | -21.79 | -21.80 | -61.10 | -5.20 | -2.20 | -4.28 |
| Weighted Avg Shares Out | 1.42M | 1.06M | 743.55K | 498.53K | 394.10K | 190.37K | 218.99K | 191.13K | 191.28K |
| Weighted Avg Shares Out (Dil) | 1.42M | 1.06M | 743.55K | 498.53K | 394.10K | 190.37K | 218.99K | 191.13K | 191.28K |
Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder
CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced receipt of a Notice of Allowance for its third U.S. patent relating...
Adial Pharmaceuticals: Opportunity Knocks For Micro Cap Targeting Multi-Billion Alcohol Use Disorder Market (NASDAQ:ADIL)
Adial is a tiny microcap attempting to convert an approved nausea and sickness treatment, Ondansetran, into a treatment for alcohol use disorder.
Why Adial's Stock Is Trading Lower Today
Adial Pharmaceuticals (NASDAQ: ADIL) shares are trading lower on Wednesday, potentially selling off after surging on Tuesday following FDA emergency use authorization for the...
Why Adial Pharmaceuticals Is Trading Higher Today
Adial Pharmaceuticals (NASDAQ: ADIL) shares are trading higher on Tuesday after the company announced the FDA has issued an emergency use authorization for the company's...
Today's Exchange Rate News 26.06.2020: Pound Tracks Sideways, Euro Weak, Dollar Steady As US Statistics Mixed
Today's Exchange Rate News 26.06.2020: Pound Tracks Sideways, Euro Weak, Dollar Steady as US Statistics Mixed
FXA: Australian Dollar Is A Once-In-A-Decade Buy
Australian dollar ETF (FXA) has been in a decade-long bear market and recently plummeted below 2009 lows along with AUD/USD. Australia's low debt-to-GDP and rec
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ...
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLabs, ...
Source: https://incomestatements.info
Category: Stock Reports